Copyright © Hobbs Medical Ventures, LLC. All Rights Reserved.
BIOTECH, PHARMA & DEVICE CONSULTING
STRATEGIES FOR SUCCESS
Hobbs Medical is well-equipped to help our clients identify, better understand and capitalize on opportunities in a dynamic and evolving marketplace.
Technology moves quickly in the medical industry and it is critical to identify emerging competitors and understand the potential impact on business. HMV can advise on how new opportunities are likely to influence market dynamics.
HMV works with executive teams to objectively and quantitatively assess your business’s current growth trajectory. We formulate a high level strategy that that identifies and prioritizes organic and inorganic opportunities to develop strategies for success.
MERGERS & ACQUISITIONS
Maintaining deal flow is essential for every medical technology company to sustain consistent growth. HMV has extensive business development and licensing experience and can provide guidance and insights for M&A activties.
Our team has diverse experience in conceiving and writing business plans as well as commercialization plans. Our approach focuses on establishing a compelling value proposition to establish a clear strategy for growth and investment.
Pursuit of a new technology begins with detailed analysis of market dynamics, competitive intelligence and strategic alliance. We leverage our first-hand experience to help your development team find, evaluate and assess new assets.
We understand the importance of executive team dynamics to drive business results. We deliver impactful coaching that enables leaders align, inspire and maximize their potential. HMV partners with you to achieve sustainable change and continual growth.
Four decades of global multi-disciplinary experience across numerous technologies and therapeutic areas.
Hobbs Medical Ventures was founded by Eamonn Hobbs, an entrepreneurial senior executive with over 40 years of demonstrated success in profitable biotech, pharma, medical device and combination drug/device product business creation and growth, general management, sales and marketing, and product development. He is a renowned expert in combination drug/device technologies, having developed and commercialized numerous combination products throughout this career.
Mr. Hobbs is well known as the former President and CEO of AngioDynamics, Inc. (NASDAQ: ANGO), a company he co-founded in 1988. He grew the company into a leading medical technology and oncology company which he took public in 2004. ANGO was the best performing medical technology IPO of the class of 2004, also earning the top honors in 2005 and 2006. It was also recognized in Business Week as a “Hot 100 Top Growth Company” for 2005 and 2006 and received a # 11 ranking in Forbes “Best 200 Small Companies” in 2006. He has lead several public pharmaceutical and biotech companies throughout his career. Formerly he was President and CEO of Antares Pharma, Inc. (NASDAQ: ATRS), a specialty pharmaceutical and drug/device combination company focused on self-injection pharmaceutical products and technologies. Prior to ATRS, he was the President and CEO of Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company specializing in a novel drug/device combination cancer therapy.
Eamonn recently served as a Visiting Scholar and Entrepreneur in Residence for the Translational Accelerator at Brigham and Women’s Hospital, Harvard Medical School where his primary role was to advise, train and develop physician-scientist inventors. The Translational Accelerator is made up of a team of experts from around the Brigham with deep knowledge on many different facets of safe and effective clinical trial design and invention development and offers a range of services for investigators . The accelerator supports the development of innovation with potential for commercialization, from pre-clinical proof-of-concept to first-in-human translational research.
In recognition of his numerous contributions to the interventional radiology specialty, he was granted an honorary fellowship by the Society of Interventional Radiology in 2005 and is one of four non-physicians to ever receive this distinction. He is a highly sought-after board director and has served on numerous public and private company boards throughout his career, including at present Syncromune, OraSure (OSUR), Marvao Medical, and Arrayus Technologies. Mr. Hobbs received a B.S. degree in Plastics Engineering with a Biomaterials emphasis at the University of Massachusetts (Lowell).
Turn today’s challenge into tomorrow’s opportunity
Hobbs Medical is based in Fort Lauderdale, FL